Skip to main content

Table 1 Trial characteristics

From: Access to routinely collected health data for clinical trials – review of successful data requests to UK registries

Trial characteristicSummary extraction: 2013–16, n (%)
n = 69
Detailed extraction: 2017–18, n (%)
n = 91
Total,
n (%)
n = 160
Purpose
 Screening6 (9%)10 (11%)16 (10%)
 Treatment51 (74%)65 (71%)116 (73%)
 Primary prevention12 (17%)16 (18%)28 (18%)
Feasibility/Pilot trial
 Yes6 (9%)11 (12%)17 (11%)
 No63 (91%)80 (88%)143 (89%)
Recruitment setting
 Primary care23 (33%)18 (20%)41 (26%)
 Secondary care46 (67%)73 (80%)119 (74%)
Disease category
 Cancer17 (25%)30 (33%)47 (29%)
 Cardiovascular and stroke21 (30%)25 (27%)46 (29%)
 Pregnancy and childbirth4 (6%)5 (5%)9 (6%)
 Mental/neurological health6 (9%)6 (7%)12 (8%)
 Infection5 (7%)3 (3%)8 (5%)
 Endocrine and diabetes1 (1%)3 (3%)4 (3%)
 Inflammatory disorder2 (3%)3 (3%)5 (3%)
 Other13 (19%)16 (18%)29 (18%)
Intervention
 Drug38 (55%)38 (42%)76 (48%)
 Surgical5 (7%)8 (9%)13 (8%)
 Other26 (38%)45 (49%)71 (44%)
Primary outcome
 Survival related33 (48%)39 (43%)72 (45%)
 Other36 (52%)52 (57%)88 (55%)
Randomisation
 Individual61 (88%)75 (82%)136 (85%)
 Cluster8 (12%)16 (18%)24 (15%)
Trial size
Median110326111590
Range41–170,43253–6,000,00041–6,000,000
 1–50021 (30%)20 (22%)41 (26%)
 500–500031 (45%)43 (47%)74 (46%)
  >500017 (25%)25 (27%)42 (26%)
 Unclear0 (0%)3 (3%)3 (2%)
International accrual
 Yes13 (19%)19 (21%)32 (20%)
 No (UK only)56 (81%)69 (76%)125 (78%)
 Unclear0 (0%)3 (3%)3 (2%)
Coordinated by registered clinical trials unit
 Yes40 (58%)63 (69%)103 (64%)
 No10 (14%)12 (13%)22 (14%)
 Unclear19 (28%)16 (18%)35 (22%)
Highest profile journal (if primary report published)
BMJNA2 (2%)2 (1%)
JAMANA6 (7%)6 (4%)
LancetNA16 (18%)16 (10%)
Lancet-specialtyNA2 (2%)2 (1%)
NEJMNA3 (3%)3 (2%)
 OtherNA6 (7%)6 (4%)
 Not yet publishedNA56 (62%)56 (35%)
 Not captured69 (100%)NA69 (43%)